Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment.
To explore the efficacy of pharmacokinetics-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment. 153 samples of advanced colorectal cancer patients were enrolled and randomly assigned into control group and experimental group. All patients received double-week chemotherapy with 5-fluorouracil (four weeks were used as one period), and chemotherapy duration ranged from 2 to 6 periods. In the first period, all patients were administrated with classic strategy of body surface area (BSA). In the subsequent periods, the control group (77 samples) continued with BSA guided chemotherapy, while experimental group (76 samples) received pharmacokinetics AUC-based chemotherapy. Efficacy and toxic side effects were assessed during chemotherapy, and survival were recorded in follow-up. In the AUC experimental group, rate of diarrhea significantly decreased (37.50% vs 70.00%, P=0.010), and events of oral mucositis reduced (54.17% vs 82.50%, P=0.014). Compared with control group, Clinical benefit rate of experimental group was much higher (90.79% vs 79.22%, P=0.046). There was no significant difference in other 5-fluorouracil related toxic side effect events (nausea, vomiting, hand-foot syndrome) and progression free survival between two groups. Pharmacokinetics-based dose management of 5-Fluorouracil reduces toxicity of chemotherapy and improved long-term efficacy of chemotherapy for advanced colorectal cancer patients.